{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T20:30:47Z","timestamp":1747168247734,"version":"3.40.5"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.neuropharm.2014.05.028","type":"journal-article","created":{"date-parts":[[2014,6,7]],"date-time":"2014-06-07T13:31:12Z","timestamp":1402147872000},"page":"284-289","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Non-ergot dopamine agonist rotigotine as a promising therapeutic tool in atypical parkinsonism syndromes: A 24 months pilot observational open-label study"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0611-1169","authenticated-orcid":false,"given":"D.V.","family":"Moretti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Binetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Zanetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.B.","family":"Frisoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.neuropharm.2014.05.028_bib1","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1136\/jnnp.74.9.1215","article-title":"Performance on the dementia rating scale in Parkinson's disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer's disease","volume":"74","author":"Aarsland","year":"2003","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"issue":"6","key":"10.1016\/j.neuropharm.2014.05.028_bib2","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2165\/00002018-200932060-00004","article-title":"Behavioural adverse effects of dopaminergic treatments in Parkinson's disease: incidence, neurobiological basis, management and prevention","volume":"32","author":"Antonini","year":"2009","journal-title":"Drug. Saf."},{"issue":"12","key":"10.1016\/j.neuropharm.2014.05.028_bib3","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.2165\/00023210-200721120-00007","article-title":"Rotigotine transdermal patch: a review of its use in the management of Parkinson's disease","volume":"21","author":"Baldwin","year":"2007","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.neuropharm.2014.05.028_bib4","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/ene.12022","article-title":"Vidailhet M.EFNS\/MDS-ES\/ENS [corrected] recommendations for the diagnosis of Parkinson's disease","volume":"20","author":"Berardelli","year":"2013","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.neuropharm.2014.05.028_bib5","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","article-title":"The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia","volume":"44","author":"Cummings","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2014.05.028_bib6","unstructured":"Fahn S, Elton RL, UPDRS Program Members. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB, editors. Recent developments in Parkinson's disease, vol. 2. Florham Park, NJ: Macmillan Healthcare Information; 1987. p 153\u2013163, 293\u2013304."},{"key":"10.1016\/j.neuropharm.2014.05.028_bib7","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u2018Mini mental state\u2019: a practical method for grading the cognitive state of patients for clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J.\u00a0Psychiatr. Res."},{"issue":"1","key":"10.1016\/j.neuropharm.2014.05.028_bib8","first-page":"94","article-title":"Othello syndrome in patients with Parkinson's disease","volume":"22","author":"Georgiev","year":"2010","journal-title":"Psychiatr. Danub"},{"key":"10.1016\/j.neuropharm.2014.05.028_bib9","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1212\/01.wnl.0000324625.00404.15","article-title":"Second consensus statement on the diagnosis of multiple system atrophy","volume":"71","author":"Gilman","year":"2008","journal-title":"Neurology"},{"year":"2012","series-title":"Tideglusib Reduces Progression of Brain Atrophy in Progressive Supranuclear Palsy in a Randomized Trial; Alzheimer's Association International Conference","author":"Hoglinger","key":"10.1016\/j.neuropharm.2014.05.028_bib10"},{"key":"10.1016\/j.neuropharm.2014.05.028_bib11","first-page":"242","article-title":"The clinical diagnosis of Parkinson\u2019s disease: proposal of diagnostic subgroups classified at different levels of confidence","volume":"84","author":"Larsen","year":"1994","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.neuropharm.2014.05.028_bib12","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/ana.23612","article-title":"A\u00a0randomized trial of mesenchymal stem cells in multiple system atrophy","volume":"72","author":"Lee","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2014.05.028_bib13","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1212\/01.wnl.0000259516.61938.bb","article-title":"Advanced Parkinson disease treated with rotigotine transdermal system: PREFER study","volume":"68","author":"LeWitt","year":"2007","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.neuropharm.2014.05.028_bib14","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s00702-012-0925-5","article-title":"Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson's disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER","volume":"120","author":"LeWitt","year":"2013","journal-title":"J.\u00a0Neural Transm."},{"issue":"Pt 7","key":"10.1016\/j.neuropharm.2014.05.028_bib15","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1093\/brain\/awq123","article-title":"Does corticobasal degeneration exist? A clinicopathological re-evaluation","volume":"133","author":"Ling","year":"2010","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.neuropharm.2014.05.028_bib16","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1111\/ane.12067","article-title":"Differentiation of progressive supranuclear palsy: clinical, imaging and laboratory tools","volume":"127","author":"Liscic","year":"2013","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.neuropharm.2014.05.028_bib17","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1136\/jnnp.60.6.615","article-title":"Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study","volume":"60","author":"Litvan","year":"1996","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neuropharm.2014.05.028_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.47.1.1","article-title":"Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop","volume":"47","author":"Litvan","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2014.05.028_bib19","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/mds.10459","article-title":"Movement disorders society scientific issues committee report: SIC task force appraisal of clinical diagnostic criteria for parkinsonian disorders","volume":"18","author":"Litvan","year":"2003","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2014.05.028_bib20","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1212\/WNL.47.5.1113","article-title":"Consensus guidelines for the clinical diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop","volume":"47","author":"McKeith","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2014.05.028_bib21","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1212\/01.wnl.0000187889.17253.b1","article-title":"Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium","volume":"65","author":"McKeith","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2014.05.028_bib22","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/1471-2377-12-131","article-title":"Treatment of multiple system atrophy using intravenous immunoglobulin","volume":"12","author":"Novak","year":"2012","journal-title":"BMC Neurol."},{"key":"10.1016\/j.neuropharm.2014.05.028_bib23","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S1474-4422(07)70108-4","article-title":"SP 515 Investigators. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson\u2019s disease: a double-blind, double-dummy, randomised controlled trial","volume":"6","author":"Poewe","year":"2007","journal-title":"Lancet Neurol."},{"issue":"Suppl.\u00a01","key":"10.1016\/j.neuropharm.2014.05.028_bib24","first-page":"1182","article-title":"A\u00a0randomized, placebo-controlled clinical trial to assess the effects of rasagiline in patients with multiple system atrophy of the parkinsonian subtype","volume":"27","author":"Poewe","year":"2012","journal-title":"Mov. Disord."},{"issue":"7","key":"10.1016\/j.neuropharm.2014.05.028_bib25","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.parkreldis.2013.02.018","article-title":"Rotigotine and specific non-motor symptoms of Parkinson's disease: post hoc analysis of RECOVER","volume":"19","author":"Ray Chaudhuri","year":"2013","journal-title":"Parkinsonism. Relat. Disord."},{"issue":"8","key":"10.1016\/j.neuropharm.2014.05.028_bib26","doi-asserted-by":"crossref","first-page":"699","DOI":"10.2165\/11206750-000000000-00000","article-title":"Rotigotine transdermal patch: a review of its use in the treatment of Parkinson's disease","volume":"25","author":"Sanford","year":"2011","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.neuropharm.2014.05.028_bib27","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.neulet.2007.12.001","article-title":"Neuroprotective effects of rotigotine in the acute MPTP-lesioned mouse model of Parkinson's disease","volume":"432","author":"Scheller","year":"2008","journal-title":"Neurosci. Lett."},{"issue":"1","key":"10.1016\/j.neuropharm.2014.05.028_bib28","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00210-008-0341-4","article-title":"The in\u00a0vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease","volume":"379","author":"Scheller","year":"2009","journal-title":"Arch. Pharmacol. Naunyn Schmiedeb."},{"key":"10.1016\/j.neuropharm.2014.05.028_bib29","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.parkreldis.2010.06.009","article-title":"High compliance with rotigotine transdermal patch in the treatment of idiopathic Parkinson's disease","volume":"16","author":"Schnitzler","year":"2010","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.neuropharm.2014.05.028_bib30","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1093\/brain\/awq115","article-title":"Rational therapeutic approaches to progressive supranuclear palsy","volume":"133","author":"Stamelou","year":"2010","journal-title":"Brain"},{"issue":"9","key":"10.1016\/j.neuropharm.2014.05.028_bib31","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1002\/mds.25509","article-title":"'Atypical' parkinsonism: new genetic disorders presenting with features of PSP, MSA or CBD","volume":"28","author":"Stamelou","year":"2013","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.neuropharm.2014.05.028_bib32","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/WCO.0b013e3283632da6","article-title":"Atypical parkinsonism: an update","volume":"26","author":"Stamelou","year":"2013","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.neuropharm.2014.05.028_bib33","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/mds.23441","article-title":"Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER)","volume":"26","author":"Trenkwalder","year":"2011","journal-title":"Mov. Disord."},{"issue":"Suppl.\u00a01","key":"10.1016\/j.neuropharm.2014.05.028_bib34","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/S1353-8020(11)70026-8","article-title":"Impulse control disorders in Parkinson's disease","volume":"18","author":"Vilas","year":"2012","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.neuropharm.2014.05.028_bib35","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1136\/jnnp.58.2.160","article-title":"Clinicopathological study of 35 cases of multiple system atrophy","volume":"58","author":"Wenning","year":"1995","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neuropharm.2014.05.028_bib36","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/mds.870120203","article-title":"Multiple system atrophy: a review of 203 pathologically proven cases","volume":"12","author":"Wenning","year":"1997","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2014.05.028_bib37","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/jnnp.67.5.620","article-title":"Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed parkinsonian syndromes: a clinicopathological study","volume":"67","author":"Wenning","year":"1999","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neuropharm.2014.05.028_bib38","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/ana.21465","article-title":"Multiple system atrophy: a primary oligodendrogliopathy","volume":"64","author":"Wenning","year":"2008","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2014.05.028_bib39","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S1474-4422(12)70327-7","article-title":"The natural history of multiple system atrophy: a prospective European cohort study","volume":"12","author":"Wenning","year":"2013","journal-title":"Lancet Neurol."},{"issue":"Pt 6","key":"10.1016\/j.neuropharm.2014.05.028_bib40","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/brain\/awh488","article-title":"Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism","volume":"128","author":"Williams","year":"2005","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2014.05.028_bib41","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S1474-4422(09)70042-0","article-title":"Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges","volume":"8","author":"Williams","year":"2009","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.neuropharm.2014.05.028_bib42","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","article-title":"Valvular heart disease and the use of dopamine agonists for Parkinson's disease","volume":"356","author":"Zanettini","year":"2007","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"7","key":"10.1016\/j.neuropharm.2014.05.028_bib43","doi-asserted-by":"crossref","first-page":"e69738","DOI":"10.1371\/journal.pone.0069738","article-title":"Rotigotine transdermal patch in Parkinson's disease: a systematic review and meta-analysis","volume":"8","author":"Zhou","year":"2013","journal-title":"PLoS One"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390814001956?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390814001956?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T10:52:07Z","timestamp":1538563927000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390814001956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":43,"alternative-id":["S0028390814001956"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2014.05.028","relation":{},"ISSN":["0028-3908"],"issn-type":[{"type":"print","value":"0028-3908"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-ergot dopamine agonist rotigotine as a promising therapeutic tool in atypical parkinsonism syndromes: A 24 months pilot observational open-label study","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2014.05.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}